{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:01:38Z","timestamp":1788930098335,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P20227KXJK"],"award-info":[{"award-number":["P20227KXJK"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022CZR88M"],"award-info":[{"award-number":["2022CZR88M"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG 2021\\u201325920"],"award-info":[{"award-number":["IG 2021\\u201325920"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA20122"],"award-info":[{"award-number":["CA20122"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.phrs.2025.107997","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:45:56Z","timestamp":1760571956000},"page":"107997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma"],"prefix":"10.1016","volume":"221","author":[{"given":"Emma","family":"Nozza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genesio","family":"Di Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Di Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mangili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Treppiedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Battistin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Di Dalmazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Peverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107997_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma \u2014 towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107997_bib2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107997_bib3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/clinem\/dgac046","article-title":"Temporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary Referral-center experience","volume":"107","author":"Daher","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2025.107997_bib4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S34956","article-title":"Current management options for recurrent adrenocortical carcinoma","author":"Sidhu","year":"2013","journal-title":"Onco Targets Ther."},{"issue":"11","key":"10.1016\/j.phrs.2025.107997_bib5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107997_bib6","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the european network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2025.107997_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113424","article-title":"Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: a population-based study","volume":"196","author":"Debets","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2025.107997_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the brescia experience","volume":"12","author":"Lagan\u00e0","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.phrs.2025.107997_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076829","article-title":"Preclinical evidence of progesterone as a new pharmacological strategy in human adrenocortical carcinoma cell lines","volume":"24","author":"Tamburello","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107997_bib10","first-page":"11690-1","article-title":"Correction: ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen, (Original article: Aging (Albany NY) (2021), 13(18), (22286\u201322297), (PMID: 34536950), (PMCID: PMC8507286), (10.18632\/aging.203534))","volume":"15","author":"Wang","year":"2023","journal-title":"Aging Impact J. LLC"},{"issue":"5","key":"10.1016\/j.phrs.2025.107997_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00018-013-1408-z","article-title":"Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer","volume":"71","author":"Szab\u00f3","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.phrs.2025.107997_bib12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/ijc.35239","article-title":"Therapeutic potential of targeting the FLNA-regulated Wee1 kinase in adrenocortical carcinomas","volume":"156","author":"Esposito","year":"2025","journal-title":"Int J. Cancer [Internet]"},{"issue":"3","key":"10.1016\/j.phrs.2025.107997_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccr.2010.08.011","article-title":"In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma","volume":"18","author":"Mir","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.phrs.2025.107997_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-009-0571-2","article-title":"Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome","volume":"122","author":"Murrow","year":"2010","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.phrs.2025.107997_bib15","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna Di Ror\u00e0","year":"2020"},{"issue":"18","key":"10.1016\/j.phrs.2025.107997_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184491","article-title":"Feasibility and activity of megestrol acetate in addition to etoposide, doxorubicin, cisplatin, and mitotane as First-Line therapy in patients with Metastatic\/Unresectable adrenocortical carcinoma with low performance status","volume":"15","author":"Turla","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.phrs.2025.107997_bib17","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.21037\/tcr-21-1993","article-title":"EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report","volume":"11","author":"Zhang","year":"2022","journal-title":"Transl. Cancer Res"},{"issue":"10","key":"10.1016\/j.phrs.2025.107997_bib18","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/1535-7163.MCT-16-0660","article-title":"A Small-Molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia","volume":"16","author":"Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"36","key":"10.1016\/j.phrs.2025.107997_bib19","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107997_bib20","article-title":"Wee1 inhibitor AZD1775 combined with cisplatin potentiates anticancer activity against gastric cancer by increasing DNA damage and cell apoptosis","volume":"2018","author":"Chen","year":"2018","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.phrs.2025.107997_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.642328","article-title":"WEE1 inhibition in combination with targeted agents and standard chemotherapy in preclinical models of pancreatic ductal adenocarcinoma","volume":"11","author":"Hartman","year":"2021","journal-title":"Front Oncol."},{"issue":"20","key":"10.1016\/j.phrs.2025.107997_bib22","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-17-2805","article-title":"The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer","volume":"24","author":"Lallo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107997_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719898373","article-title":"WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma","volume":"11","author":"de Jong","year":"2020","journal-title":"Ther. Adv. Hematol."},{"issue":"23","key":"10.1016\/j.phrs.2025.107997_bib24","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1158\/0008-5472.CAN-19-1961","article-title":"Upregulation of MyT1 promotes acquired resistance of cancer cells to WEE1 inhibition","volume":"79","author":"Lewis","year":"2019","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.phrs.2025.107997_bib25","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.21037\/tlcr-21-973","article-title":"The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies","volume":"10","author":"Shao","year":"2021","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.phrs.2025.107997_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1270542","article-title":"Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors","volume":"11","author":"Sokhi","year":"2023","journal-title":"Front Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107997_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/ERC-13-0439","article-title":"Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model","volume":"21","author":"Hantel","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.phrs.2025.107997_bib28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2025.107997_bib29","article-title":"Anti-Tumor effects of Wee1 kinase inhibitor with radiotherapy in human cervical cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.phrs.2025.107997_bib30","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1111\/cas.15051","article-title":"Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer","volume":"112","author":"Murakami","year":"2021","journal-title":"Cancer Sci."},{"issue":"JULY","key":"10.1016\/j.phrs.2025.107997_bib31","article-title":"Wee1 inhibitor AZD1775 effectively inhibits the malignant phenotypes of esophageal squamous cell carcinoma in vitro and in vivo","volume":"10","author":"Bi","year":"2019","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2025.107997_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00052","article-title":"A new mouse avatar model of Non-Small cell lung cancer","volume":"5","author":"Russo","year":"2015","journal-title":"Front Oncol."},{"key":"10.1016\/j.phrs.2025.107997_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714132","article-title":"Immune checkpoints expression in chronic lung allograft rejection","volume":"12","author":"Righi","year":"2021","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107997_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinforma."},{"key":"10.1016\/j.phrs.2025.107997_bib35","first-page":"2698","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021"},{"issue":"3","key":"10.1016\/j.phrs.2025.107997_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1091581813484366","article-title":"Corticosteroid production in H295R cells during exposure to 3 endocrine disrupters analyzed with LC-MS\/MS","volume":"32","author":"Winther","year":"2013","journal-title":"Int J. Toxicol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107997_bib37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin. Endocrinol. (Oxf. )"},{"key":"10.1016\/j.phrs.2025.107997_bib38","first-page":"307","article-title":"Current status and future direction in the treatment of advanced adrenocortical carcinoma","volume":"26","author":"Pak","year":"2024"},{"issue":"7","key":"10.1016\/j.phrs.2025.107997_bib39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"Hirai","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.phrs.2025.107997_bib40","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Hirai","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.phrs.2025.107997_bib41","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","article-title":"MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts","volume":"17","author":"Rajeshkumar","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107997_bib42","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.22.00830","article-title":"Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification","volume":"41","author":"Fu","year":"2022","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.phrs.2025.107997_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","article-title":"Adavosertib with chemotherapy in patients with primary Platinum-Resistant ovarian, fallopian tube, or peritoneal cancer: an Open-Label, Four-Arm, phase II study","volume":"28","author":"Moore","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107997_bib44","first-page":"432","article-title":"An update on adrenocortical cell lines of human origin","volume":"77","author":"Sigala","year":"2022"},{"issue":"30","key":"10.1016\/j.phrs.2025.107997_bib45","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2014.60.4009","article-title":"Phase I study of single-agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors","volume":"33","author":"Do","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107997_bib46","first-page":"373","article-title":"Dose translation between laboratory animals and human in preclinical and clinical phases of drug development","volume":"79","author":"Nair","year":"2018"},{"issue":"11","key":"10.1016\/j.phrs.2025.107997_bib47","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/jcph.2492","article-title":"Population pharmacokinetic modeling of adavosertib (AZD1775) in patients with solid tumors","volume":"64","author":"Johnson","year":"2024","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2025.107997_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jc.2005-1739","article-title":"Review: emerging treatment strategies for adrenocortical carcinoma: a new hope","volume":"91","author":"Kirschner","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2025.107997_bib49","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ijc.32515","article-title":"Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer","volume":"146","author":"Takashima","year":"2020","journal-title":"Int J. Cancer"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:59:36Z","timestamp":1773179976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":49,"alternative-id":["S1043661825004220"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107997","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107997"}}